Clene Inc.
Clene Inc. is a U.S.-based pharmaceutical preparations company that also sells dietary mineral supplements through its subsidiary and commercial partners. The company’s reported revenue is currently small and comes mainly from sales of Zinc Factor, Gold Factor, and rMetx ZnAg Immune Boost, while most of its resources remain focused on research and development of drug candidates.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAqueous zinc-silver and gold mineral supplement products sold directly or through 4Life.
License-based royalties tied to Gold Factor sales under an exclusive agreement with 4Life.
Research and development programs aimed at advancing Clene’s therapeutic pipeline.
Products
Reported · share of revenue- Products59.5 %
- Royalty40.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Clene sells its supplement products through a mix of direct subsidiary sales and a commercial supply/license relationship with 4Life, which appears to be the key channel partner. The customer base is therefore concentrated in a small number of commercial counterparties rather than broad retail distribution. The company’s R&D activity is aimed at future pharmaceutical customers and regulators, but current monetization is still centered on supplement products and royalties.
Buys Zinc Factor and Gold Factor under supply and license arrangements and drives most current product and royalty revenue.
Purchasers of rMetx ZnAg Immune Boost through Clene’s wholly owned subsidiary.
Potential future patients, prescribers, and healthcare systems for Clene’s drug candidates.
Strategy
Clene’s near-term strategy is to preserve liquidity while continuing to develop its drug candidates and maintain limited supplement commercialization. Management is explicitly pursuing additional capital through equity, debt, licensing, collaboration, and ATM financing, while also cutting costs and slowing some R&D and commercialization work. The company’s strategic challenge is to bridge from a small, partner-driven supplement revenue base to a sustainable biotech platform.
The company has recurring losses and substantial doubt about going concern, so funding is essential to continue operations.
Lowering cash burn extends runway while the company seeks external capital and advances its pipeline.
Long-term value depends on converting R&D into viable therapeutic products beyond the current supplement business.
Geography
Clene is incorporated in Delaware and operates with subsidiaries in Australia and the Netherlands, reflecting a small international operating footprint. The reports do not disclose country-level revenue, so the business appears operationally global but commercially concentrated in a limited number of partner relationships. Geography matters mainly through tax credits in Australia, foreign subsidiary structure, and the company’s U.S. capital markets exposure on Nasdaq.
Risks
Clene faces acute financing and listing risk because it has sustained losses, negative operating cash flow, and a Nasdaq MVLS deficiency notice. Its current revenue base is small and concentrated in a few supplement-related agreements, so any disruption in partner purchases or commercialization could materially affect results. As a development-stage biotech, it also carries typical clinical, regulatory, and execution risk, while fair-value and convertible-instrument accounting can create volatility in reported earnings.
Management states it has incurred significant losses and expects additional losses, with plans dependent on raising new capital.
Exposure: Cash runway and financing access
The company received a notice that its market value of listed securities was below the minimum requirement and may be delisted if it does not regain compliance.
Exposure: Nasdaq continued listing requirements
Current revenue depends heavily on 4Life-related supply and license arrangements and timing of purchases.
Exposure: Product and royalty revenue
Future value depends on advancing drug candidates through research, development, and eventual commercialization.
Exposure: Pipeline programs
Accounting
Judgemental itemsProduct and royalty revenue depend on the timing of 4Life purchases and sales, which can cause quarter-to-quarter volatility.
Impact: Affects reported revenue and comparability across periods
Changes in Clene’s stock price and valuation assumptions drive non-cash gains or losses.
Impact: Can materially affect net income without changing cash flow
These instruments require judgment on classification and measurement, and can create balance sheet and earnings volatility.
Impact: Affects liabilities, interest/other income, and dilution analysis
Management has recorded a full allowance because future taxable income is uncertain.
Impact: Limits recognition of tax benefits and signals ongoing losses
Similar listed companies
Publicly listed companies with a comparable business focus.
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
LENZ Therapeutics, Inc.
LENZ · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia.
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Zhengye Biotechnology Holding Ltd
ZYBT · Pharmaceutical Preparations
Zhengye Biotechnology Holding Ltd is a Cayman Islands holding company with operating activities centered in Jilin, China through its veterinary vaccine business.
Gelteq Ltd
GELS · Pharmaceutical Preparations
Gelteq Ltd is a U.S.-listed pharmaceutical preparations company that develops and commercializes dosage-formulation and drug-delivery solutions through its corporate and financing structure.
Last updated: 24/09/2026